The application discloses a
temozolomide dexchlorpheniramine derivative and application thereof in preparation of an antitumor
drug, and is based on new
cognition of a TMZ
drug resistance mechanism, designs and synthesizes two
temozolomide derivatives. The target compounds retain the alkylating activity of TMZ, and metabolites do not produce 5-amino-
imidazole-4
amide (AICA), but produce dexchlorpheniramine derivatives of AICA. Thus, the TMZ
chemotherapy sensitivity is enhanced, and the TMZ
drug resistance of
glioma is delayed or reversed. The application first reconstructs the TMZ molecule from the metabolic product level, breaks through the action mode of the inherent
drug resistance, and provides a brand-new
drug design idea for overcoming the TMZ
drug resistance. A new generation of TMZ derivative drugs can be developed, a single drug or a
combined treatment scheme with higher
efficacy and lower
drug resistance is realized, and more breakthrough
treatment options are provided for GBM patients.